Stock SRPT SAREPTA THERAPEUTICS, INC.
Add to a list

Sarepta Therapeutics, Inc. Share Price

Stocks

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 01:30:00 18/07/2026 am IST 		5-day change 1st Jan Change
17.22 USD -0.06% Intraday chart for Sarepta Therapeutics, Inc. -9.13% -19.98%
30/06 Sarepta Therapeutics Announces FDA Acceptance Of Supplemental New Drug Applications For Amondys 45 And Vyondys 53 For Duchenne Muscular Dystrophy CI
30/06 Sarepta Therapeutics Gets FDA Review for Duchenne Muscular Dystrophy Applications MT

Valuation: Sarepta Therapeutics, Inc.

Market Cap 181.8Cr 158.88Cr 146.61Cr 135.14Cr 254.7Cr 18TCr 260.36Cr 1.75TCr 689.23Cr 8.57TCr 682.76Cr 667.78Cr 30TCr P/E 2026 *
4.88x
P/E 2027 * 24.9x
Enterprise Value 131.67Cr 115.07Cr 106.18Cr 98Cr 184.47Cr 13TCr 188.57Cr 1.27TCr 499.19Cr 6.21TCr 494.5Cr 483.65Cr 21TCr EV / Sales 2026 *
0.72x
EV / Sales 2027 * 0.65x
Free-Float
95.19%
Yield 2026 *
-
Yield 2027 * -
* Estimated data More valuation ratios

Chart: Sarepta Therapeutics, Inc.

Dynamic Chart

Latest news : Sarepta Therapeutics, Inc.

30/06 Sarepta Therapeutics Announces FDA Acceptance Of Supplemental New Drug Applications For Amondys 45 And Vyondys 53 For Duchenne Muscular Dystrophy CI
30/06 Sarepta Therapeutics Gets FDA Review for Duchenne Muscular Dystrophy Applications MT
30/06 Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell 1000 Index CI
29/06 Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 2000 Index CI
29/06 Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell Midcap Growth Benchmark CI
29/06 Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 2000 Value Benchmark CI
29/06 Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 2000 Growth Benchmark CI
29/06 Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell 1000 Growth Benchmark CI
29/06 Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell 1000 Dynamic Index CI
29/06 Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 2000 Dynamic Index CI
29/06 Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell Midcap Value Benchmark CI
29/06 Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell Midcap Index CI
29/06 Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell 1000 Value Benchmark CI
More news

Last Transcript: Sarepta Therapeutics, Inc.

Logo Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 10:40 AM
08/06
More transcripts

Analysts' recommendations: Sarepta Therapeutics, Inc.

18/06 Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says MT
15/05 Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says MT
08/05 Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says MT
17/04 Sarepta Therapeutics Seen Benefiting From New Elevidys Study, Better US Uptake in Second Half of 2026 MT
07/04 RBC Adjusts Price Target on Sarepta Therapeutics to $19 From $18, Maintains Sector Perform Rating MT
More recommendations

Press Releases: Sarepta Therapeutics, Inc.

01/07 Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45(R) and VYONDYS 53(R) AQ
01/07 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BU
30/06 Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53® BU
02/06 Sarepta Therapeutics to Participate in Upcoming Investor Conferences BU
14/05 Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference BU
More press releases

News in other languages: Sarepta Therapeutics, Inc.

16/04 Roche entame une étude de phase III sur la thérapie Elevidys
16/04 Roche startet neue Phase-III-Studie mit Gentherapie Elevidys
27/02 Sarepta Therapeutics anuncia la convocatoria de solicitudes para la 9º edición anual de Route 79, el programa de becas de Duchenne
04/11 Palantir Technologies : , Spotify, Starbucks...les valeurs à suivre aujourd'hui à Wall Street -
04/11 Wall Street neemt adempauze
More news

Quotes and Performance

1 day-0.06%
1 week-9.13%
Current month-4.17%
1 month-1.77%
3 months-20.09%
6 months-18.50%
Current year-19.98%
More quotes

Course Extremes

1 week 16.65
Extreme 16.65
 19.36
1 month 15.79
Extreme 15.79
 20.88
Current year 14.68
Extreme 14.68
 24.68
1 year 10.42
Extreme 10.415
 25.32
3 years 10.42
Extreme 10.415
 173.25
5 years 10.42
Extreme 10.415
 173.25
10 years 10.42
Extreme 10.415
 181.83
More quotes

Managers and Directors: Sarepta Therapeutics, Inc.

Manager TitleAgeSince
Douglas Ingram CEO
 Chief Executive Officer 63 26/06/2017
Ryan Wong DFI
 Director of Finance/CFO 47 16/07/2025
Ian Estepan DFI
 Director of Finance/CFO 50 14/12/2020
Director TitleAgeSince
M. Wilsey CHM
 Chairman 73 16/04/2015
Hans Lennart Rudolf Wigzell BRD
 Director/Board Member 87 01/06/2010
Richard Barry BRD
 Director/Board Member 67 02/06/2015
More insiders

Latest insider transactions

Date Insider Type Main position Quantity % Market Cap.
04/06/26
Kathryn Boor
Free

Director

16,875 0.0160%
04/06/26
Michael Chambers
Free

Director

16,875 0.0160%
04/06/26
Claude Nicaise
Free

Director

16,875 0.0160%
Transaction History

Diagnostic & Testing Substances Manufacturers

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
-0.06%-9.13%+22.34%-83.85% 181.8Cr
ULTRAGENYX PHARMACEUTICAL INC. Stock Ultragenyx Pharmaceutical Inc.
-3.11%-13.42%+11.29%-33.77% 287.5Cr
BIONOTE, INC. Stock BioNote, Inc.
+0.53%-0.32%-11.32%-14.70% 32Cr
DK LIFE SCIENCE CO., LTD. Stock DK Life Science Co., Ltd.
-0.42%-4.05%-47.22% - 5.1Cr
Average -0.76%-6.73%-6.23%-44.11% 126.6Cr
Weighted average by Cap. -1.76%-10.96%+13.24%-50.72%
See all sector performances

Financials

2026 *2027 *
Net sales 183.95Cr 160.75Cr 148.34Cr 136.73Cr 257.71Cr 18TCr 263.43Cr 1.77TCr 697.37Cr 8.68TCr 690.82Cr 675.67Cr 30TCr 140.04Cr 122.38Cr 112.93Cr 104.09Cr 196.2Cr 13TCr 200.55Cr 1.35TCr 530.91Cr 6.6TCr 525.92Cr 514.38Cr 23TCr
Net income 42Cr 37Cr 34Cr 31Cr 59Cr 4.03TCr 60Cr 403.03Cr 158.52Cr 1.97TCr 157.03Cr 153.59Cr 6.79TCr 6.85Cr 5.98Cr 5.52Cr 5.09Cr 9.59Cr 659.21Cr 9.8Cr 66Cr 26Cr 322.86Cr 26Cr 25Cr 1.11TCr
Net Debt -50Cr -44Cr -40Cr -37Cr -70Cr -4.83TCr -72Cr -483.18Cr -190.05Cr -2.36TCr -188.26Cr -184.13Cr -8.14TCr -90Cr -79Cr -73Cr -67Cr -126.31Cr -8.68TCr -129.12Cr -869.02Cr -341.8Cr -4.25TCr -338.59Cr -331.17Cr -15TCr
* Estimated data More financial data

Company Profile

Logo Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.
Employees
835
Sector
Pharmaceuticals
More about the company

Quotes

Date Price Change Volume
17/26/17 $17.22 -0.06% 53,99,159
16/26/16 $17.23 -2.16% 31,80,760
15/26/15 $17.61 -1.95% 35,08,809
14/26/14 $17.96 -4.57% 29,62,206
13/26/13 $18.82 -0.69% 24,57,719

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
17.22USD
Average target price
22.17USD
Spread / Average Target
+28.77%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Stocks
  3. SRPT Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition